Anavex Life Sciences Stock (NASDAQ:AVXL)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$9.02

52W Range

$3.25 - $10.45

50D Avg

$6.40

200D Avg

$5.30

Market Cap

$772.49M

Avg Vol (3M)

$997.14K

Beta

0.60

Div Yield

-

AVXL Company Profile


Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

40

IPO Date

Aug 02, 2006

Website

AVXL Performance


AVXL Financial Summary


Sep 23Sep 22Sep 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Sep 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 06, 24 | 12:19 PM
Q1 24Feb 07, 24 | 12:46 PM
Q4 23Nov 27, 23 | 9:52 AM

Peer Comparison


TickerCompany
TGTXTG Therapeutics, Inc.
BTAIBioXcel Therapeutics, Inc.
IOVAIovance Biotherapeutics, Inc.
EXELExelixis, Inc.
RNAZTransCode Therapeutics, Inc.
VKTXViking Therapeutics, Inc.
AXSMAxsome Therapeutics, Inc.
BIVIBioVie Inc.
KODKodiak Sciences Inc.
EYENEyenovia, Inc.
SAVACassava Sciences, Inc.
CGTXCognition Therapeutics, Inc.
NVAXNovavax, Inc.
ANVSAnnovis Bio, Inc.
INMBINmune Bio, Inc.
MDGLMadrigal Pharmaceuticals, Inc.